Lowest Price Guaranteed
Slides
Not Available
Last Updated
October 2023
View Count
11193
Section 1: Market Overview
Section 2: Dashboard: Pipeline Analysis
Section 3: Molecules in Clinical Development: Trial Details
Section 4: Molecules in Preclinical Development: Trial Details
Section 5: Excluded Drugs
Section 6: Inclusion / Exclusion Criteria
Figure 1: Molecules in Clinical Development: Distribution by Companies
Figure 2: Molecules in Clinical Development: Distribution by Highest Phase of Development
Figure 3: Molecules in Clinical Development: Distribution by Treatment Target
Figure 4: Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
Figure 5: Clinical Trials: Distribution by Trial Status
Figure 6: Clinical Trials: Distribution by Trial Phase
Figure 7: Clinical Trials: Distribution by Route of Administration
Figure 8: Clinical Trials: Distribution by Sponsor Type
Figure 9: Clinical Trials: Distribution by Region
Figure 10A: Clinical Trials: Distribution by Molecules and Regions (Matrix View) – Set 1
Figure 10B: Clinical Trials: Distribution by Molecules and Regions (Matrix View) – Set 2
Figure 10C: Clinical Trials: Distribution by Molecules and Regions (Matrix View) – Set 3
Figure 11: Clinical Trials: Distribution by G7 Countries
Figure 12: Clinical Trials: Distribution by EU5 Countries
Table 1: Molecules in Clinical Development: Pipeline Details
Table 2: Molecules in Preclinical Development: Pipeline Details
The following companies and organisations have been mentioned in the report: